Sage Therapeutics (SAGE) News Today $7.17 -0.13 (-1.78%) Closing price 05/5/2025 04:00 PM EasternExtended Trading$7.17 0.00 (0.00%) As of 05/5/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period HC Wainwright Issues Optimistic Estimate for SAGE EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - HC Wainwright raised their Q2 2025 earnings estimates for Sage Therapeutics in a research note issued on Wednesday, April 30th. HC Wainwright analyst D. Tsao now anticipates that the biopharmaceutical company will post earnings per share of ($May 4 at 7:15 AM | marketbeat.comWedbush Equities Analysts Raise Earnings Estimates for SAGESage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Stock analysts at Wedbush lifted their Q2 2025 earnings per share estimates for shares of Sage Therapeutics in a research note issued on Tuesday, April 29th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company will post eMay 4 at 7:15 AM | marketbeat.comSusquehanna Fundamental Investments LLC Invests $1.17 Million in Sage Therapeutics, Inc. (NASDAQ:SAGE)Susquehanna Fundamental Investments LLC acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 215,8May 4 at 4:28 AM | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Rating Upgraded by StockNews.comMay 4 at 4:19 AM | americanbankingnews.comWedbush Research Analysts Lift Earnings Estimates for SAGEMay 4 at 1:19 AM | americanbankingnews.comQ2 EPS Estimate for Sage Therapeutics Raised by AnalystMay 4 at 1:19 AM | americanbankingnews.comBrokers Issue Forecasts for SAGE Q1 EarningsSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Sage Therapeutics in a note issued to investors on Wednesday, April 30th. HC Wainwright analyst D. Tsao expects that the biopharmaceutiMay 3 at 8:36 AM | marketbeat.comCaligan Partners LP Makes New Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)Caligan Partners LP acquired a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 3,052,538 shares of the biopharmaMay 3 at 7:44 AM | marketbeat.comPDT Partners LLC Buys 63,804 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)PDT Partners LLC lifted its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 37.2% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 235,097 shares of the biopharmaceutical company's sMay 3 at 6:00 AM | marketbeat.comAnalysts Set Expectations for SAGE Q1 EarningsMay 2, 2025 | americanbankingnews.comSage Therapeutics (NASDAQ:SAGE) Releases Earnings Results, Misses Estimates By $0.01 EPSSage Therapeutics (NASDAQ:SAGE - Get Free Report) released its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($1.00) by ($0.01). Sage Therapeutics had a negative net margin of 971.50% and a negative return on equity of 68.18%.May 1, 2025 | marketbeat.comQ1 2025 SAGE Therapeutics Inc Earnings CallMay 1, 2025 | finance.yahoo.comSage Therapeutics Inc (SAGE) Q1 2025 Earnings Call Highlights: Strong Demand for ZURZUVAE and ...May 1, 2025 | finance.yahoo.comVirtus ETF Advisers LLC Buys 33,029 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Virtus ETF Advisers LLC grew its position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 115.3% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 61,668 shares of the biopharmaceuticalApril 30, 2025 | marketbeat.comSage Therapeutics, Inc. (SAGE) Q1 2025 Earnings Call TranscriptApril 29, 2025 | seekingalpha.comWhat to Expect from Sage Therapeutics's EarningsApril 29, 2025 | benzinga.comSage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business UpdatesApril 29, 2025 | finance.yahoo.comBoothbay Fund Management LLC Buys New Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)Boothbay Fund Management LLC purchased a new position in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,388,503 shares of the biopharmaceutical company's sApril 28, 2025 | marketbeat.comRenaissance Technologies LLC Sells 62,505 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Renaissance Technologies LLC trimmed its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 12.2% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 450,795 shares of the biopharmaceutical company's stockApril 28, 2025 | marketbeat.comExpert Outlook: Sage Therapeutics Through The Eyes Of 4 AnalystsApril 27, 2025 | nasdaq.comNeedham & Company LLC Reiterates "Hold" Rating for Sage Therapeutics (NASDAQ:SAGE)Needham & Company LLC reiterated a "hold" rating on shares of Sage Therapeutics in a research report on Friday.April 27, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Walleye Capital LLCWalleye Capital LLC cut its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 75.5% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 56,073 shares of the biopharmaceutical company's stock afterApril 27, 2025 | marketbeat.comNew Hope for Advanced Cancer Patients: SAGE Showcases Treatment-Matching via Functional Precision Oncology at AACR 2025April 24, 2025 | finance.yahoo.comSage Therapeutics (SAGE) Projected to Post Quarterly Earnings on TuesdaySage Therapeutics (NASDAQ:SAGE) will be releasing its Q1 2025 earnings after the market closes on Tuesday, April 29. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-4-29-sage-therapeutics-inc-stock/)April 23, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Recommendation of "Hold" by AnalystsShares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) have earned a consensus rating of "Hold" from the nineteen research firms that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, fifteen have given a hold rating and twApril 23, 2025 | marketbeat.comKuehn Law Encourages Investors of Sage Therapeutics, Inc. to Contact Law FirmApril 22, 2025 | prnewswire.comQ1 EPS Estimate for Sage Therapeutics Raised by AnalystSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Research analysts at Wedbush lifted their Q1 2025 EPS estimates for Sage Therapeutics in a research report issued to clients and investors on Wednesday, April 16th. Wedbush analyst L. Chico now forecasts that the biopharmaceutical company willApril 20, 2025 | marketbeat.comQ1 Earnings Forecast for SAGE Issued By WedbushSage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) - Equities research analysts at Wedbush issued their Q1 2026 earnings estimates for Sage Therapeutics in a note issued to investors on Wednesday, April 16th. Wedbush analyst L. Chico anticipates that the biopharmaceutical company will post earniApril 19, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Sold by Vanguard Group Inc.Vanguard Group Inc. decreased its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 16.0% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,838,169 shares of the biopharmaceuticApril 16, 2025 | marketbeat.comFederated Hermes Inc. Has $6 Million Stake in Sage Therapeutics, Inc. (NASDAQ:SAGE)Federated Hermes Inc. grew its holdings in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 63.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,105,779 shares of the biopharmaceutical compaApril 14, 2025 | marketbeat.comExodusPoint Capital Management LP Makes New $759,000 Investment in Sage Therapeutics, Inc. (NASDAQ:SAGE)ExodusPoint Capital Management LP purchased a new stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 139,748 shares of the biopharmaceutiApril 14, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Position Lessened by American Century Companies Inc.American Century Companies Inc. lowered its stake in shares of Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 67.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 106,792 shares of the biopharmaceutical company'sApril 14, 2025 | marketbeat.comSAGE SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Sage Therapeutics, Inc. (NASDAQ: SAGE) and Encourages Long-Term SAGE Investors to Contact the FirmApril 10, 2025 | globenewswire.comADAR1 Capital Management LLC Cuts Stock Holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE)ADAR1 Capital Management LLC reduced its position in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 68.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 19,200 shares of the biopharmaceutical compaApril 10, 2025 | marketbeat.comSage Therapeutics: A Speculative Play That Needs To Wait For A Turnaround StoryApril 9, 2025 | seekingalpha.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Purchased by Thrivent Financial for LutheransThrivent Financial for Lutherans raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 108.7% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 74,625 shares of the biopharmaceApril 5, 2025 | marketbeat.comFox Run Management L.L.C. Acquires 32,579 Shares of Sage Therapeutics, Inc. (NASDAQ:SAGE)Fox Run Management L.L.C. increased its holdings in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 199.0% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 48,950 shares of the biopharmaceutical company's stockMarch 29, 2025 | marketbeat.comScotiabank Reaffirms Their Buy Rating on Tempest Therapeutics (TPST)March 29, 2025 | markets.businessinsider.comSage Therapeutics, Inc. (NASDAQ:SAGE) Given Consensus Rating of "Hold" by AnalystsSage Therapeutics, Inc. (NASDAQ:SAGE - Get Free Report) has received a consensus rating of "Hold" from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. Two analysts have rated the stock with a sell recommendation, fifteen have assigned a hold recommendationMarch 28, 2025 | marketbeat.comSage Therapeutics, Inc. (NASDAQ:SAGE) Shares Bought by Connor Clark & Lunn Investment Management Ltd.Connor Clark & Lunn Investment Management Ltd. raised its stake in Sage Therapeutics, Inc. (NASDAQ:SAGE - Free Report) by 157.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 169,057 shares of the biopharmMarch 21, 2025 | marketbeat.comSage Therapeutics (SAGE) Up 7.4% Since Last Earnings Report: Can It Continue?March 13, 2025 | msn.comSage Therapeutics (NASDAQ:SAGE) Earns Underperform Rating from Analysts at Bank of AmericaBank of America began coverage on shares of Sage Therapeutics in a research report on Tuesday. They issued an "underperform" rating and a $5.00 price target on the stock.March 12, 2025 | marketbeat.comSage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above Fifty Day Moving Average - What's Next?Sage Therapeutics (NASDAQ:SAGE) Stock Price Crosses Above 50 Day Moving Average - Time to Sell?March 11, 2025 | marketbeat.comSage Therapeutics resumed with an Underperform at BofAMarch 10, 2025 | markets.businessinsider.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): Grabar Law Office Investigates Claims on Your Behalf as Certain Class Actions Move ForwardMarch 10, 2025 | financialpost.comAttention Long-Term Shareholders of Driven Brands Holdings, Inc. (NASDAQ: DRVN); Mercury Systems, Inc. (NASDAQ: MRCY); Playstudios, Inc. (NASDAQ: MYPS); and Sage Therapeutics, Inc. (NASDAQ: SAGE): GraMarch 10, 2025 | investing.comGrabar Law Office Investigates Claims on Behalf of Shareholders of Sage Therapeutics, Inc. (SAGE)March 8, 2025 | investing.comSage’s medical chief is latest leader to leave biotechMarch 5, 2025 | bizjournals.comSigns of hiring at Boston-area life sciences companiesMarch 5, 2025 | bizjournals.comSage Therapeutics Chief Medical Officer to step downMarch 4, 2025 | markets.businessinsider.com Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address SAGE Media Mentions By Week SAGE Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SAGE News Sentiment▼0.620.72▲Average Medical News Sentiment SAGE News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SAGE Articles This Week▼279▲SAGE Articles Average Week Get Sage Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SAGE and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEAYA Biosciences News Today Galapagos News Today Apogee Therapeutics News Today Janux Therapeutics News Today Agios Pharmaceuticals News Today Edgewise Therapeutics News Today Harmony Biosciences News Today Disc Medicine News Today Indivior News Today Vera Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:SAGE) was last updated on 5/6/2025 by MarketBeat.com Staff From Our PartnersElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredShocking AI play that’s beats Nvidia by a country mileYou’ve seen the headlines about Nvidia. Now Tim Sykes is sounding the alarm — because what CEO Jensen Huang is...Timothy Sykes | SponsoredMost traders are panicking. We’re cashing inMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredTrump’s Bitcoin Reserve is No Accident…Crypto policy is changing fast… Smart investors are positioning themselves to benefit. And it's all happeni...Crypto 101 Media | SponsoredElon Musk is all in on these robots …Robots — built by Nvidia. Forbes says this could be " a $24 trillion opportunity for investors." Huang s...Weiss Ratings | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sage Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sage Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy SAGE Stock Free SAGE Stock Alerts